Home/Filings/4/0001209191-09-049447
4//SEC Filing

Protalix BioTherapeutics, Inc. 4

Accession 0001209191-09-049447

$PLXCIK 0001006281operating

Filed

Oct 20, 8:00 PM ET

Accepted

Oct 21, 8:02 PM ET

Size

14.9 KB

Accession

0001209191-09-049447

Insider Transaction Report

Form 4
Period: 2009-10-19
Aviezer David
DirectorPresident & CEO
Transactions
  • Exercise/Conversion

    Common Stock

    2009-10-21$0.12/sh+247,490$29,6990 total(indirect: By Trust)
  • Tax Payment

    Common Stock

    2009-10-21$9.13/sh3,253$29,7000 total(indirect: By Trust)
  • Sale

    Common Stock

    2009-10-19$9.43/sh150,000$1,414,5000 total(indirect: By Trust)
  • Sale

    Common Stock

    2009-10-20$9.45/sh60,000$567,0000 total(indirect: By Trust)
  • Sale

    Common Stock

    2009-10-21$9.36/sh34,238$320,4680 total(indirect: By Trust)
  • Exercise/Conversion

    Stock Options (Right to Buy)

    2009-10-21247,490326,267 total
    Exercise: $0.12Exp: 2013-12-08Common Stock (247,490 underlying)
Footnotes (5)
  • [F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
  • [F2]The reporting person acquired 244,237 shares of common stock upon the exercise of 247,490 outstanding options on a cash-less exercise basis, all of which shares were sold by the reporting person. The Company retained 3,253 shares of common stock in connection with the cashless exercise.
  • [F3]To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee upon the exercise of stock options must be registered in the name of a trustee.
  • [F4]All these options are fully vested.
  • [F5]Does not include options to purchase 977,296 shares of common stock at an exercise price equal to $0.972 per share that expire on September 10, 2016, options to purchase 600,000 shares of common stock at an exercise price equal to $5.00 per share that expire on February 7, 2018, and options to purchase 100,000 shares of common stock at an exercise price equal to $2.65 that expire on February 25, 2019.

Issuer

Protalix BioTherapeutics, Inc.

CIK 0001006281

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001006281

Filing Metadata

Form type
4
Filed
Oct 20, 8:00 PM ET
Accepted
Oct 21, 8:02 PM ET
Size
14.9 KB